Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cefiderocol
90%
Complicated Infections
90%
Urinary Tract
90%
Antimicrobial Resistance
90%
Adverse Effects
90%
Community-dwelling Adults
90%
Tizanidine
90%
Baclofen
90%
Janus Kinase Inhibitors (JAKi)
90%
Continuous Venovenous Hemodiafiltration (CVVHDF)
90%
Healthcare Professionals
90%
Physiologically-based Pharmacokinetic Model
90%
Ulcerative Colitis
90%
Lessons Learned
90%
Point-of-care
90%
Pharmacy
90%
Tofacitinib
90%
Healthcare Decisions
90%
Transitional Care
90%
Attention Deficit Hyperactivity Disorder Medication
90%
Digoxin
90%
Cardiovascular Adverse Events
90%
Mentorship
90%
Medication Adverse Events
90%
Drug Labeling
90%
Career Pathways
90%
Mentoring Program
90%
Escape Room
90%
Risk Communication
90%
Innovative Approaches
90%
Postgraduate Training
90%
Elective Course
90%
Student Perceptions
90%
Cross-national Comparison
90%
Pharmacy Students
84%
Health Consumers
68%
Adverse Events
68%
Training Workshop
60%
National Rate
60%
Matching Rate
60%
Pharmacy Residency Match
60%
College of Pharmacy
60%
Recurrent Urinary Tract Infections (rUTI)
45%
Janus Kinase 1 (JAK1)
45%
Causal Relationship
45%
Product Labeling
45%
Cardiovascular Risk
45%
Knowledge Assessment
36%
Active Knowledge
36%
Federal Drug Administration
30%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
90%
Janus Kinase Inhibitor
90%
Digoxin
90%
Physiologically Based Pharmacokinetic Modelling
90%
Risk Communication
90%
Attention Deficit Disorder
90%
Drug Labeling
90%
Tofacitinib
90%
Ulcerative Colitis
90%
Cefiderocol
90%
Antibiotic Resistance
90%
Infection Complication
90%
Cardiovascular Risk
68%
Urinary Tract Infection
56%
Janus Kinase
30%
Sudden Death
22%
Elevated Blood Pressure
22%
Heart Infarction
22%
Cerebrovascular Accident
22%
Carbapenemase
22%
Hypotension
18%
Atrial Fibrillation
18%
Hypertensive Factor
18%
Therapeutic Drug Monitoring
18%
Cefaclor
15%
Digestive System Inflammation
15%
Cytokine
15%
Inflammatory Bowel Disease
15%
Remission
15%
Pharmacokinetics
15%
Diseases
15%
Pathogenesis
15%
Etiology
15%
Siderophore
11%
Antibiotic-Resistant Bacteria
11%
Cephalosporin
11%
Prevalence
11%
Infection
11%
Pyelonephritis
11%
Antiinfective Agent
11%
Recurrent Disease
11%
Antimicrobial Agent
11%
Elimination
11%
Bacterium
11%
Medicine and Dentistry
Oral
100%
Tofacitinib
90%
Infection Complication
90%
Janus Kinase Inhibitor
90%
Urinary Tract
90%
Tizanidine
90%
Antibiotic Resistance
90%
Cefiderocol
90%
Ulcerative Colitis
90%
Adverse Effect
90%
Baclofen
90%
Systematic Review
90%
Urinary Tract Infection
56%
Janus Kinase
30%
Drug Administration
27%
Adverse Event
27%
Carbapenemase
22%
Brain Disease
18%
Cefaclor
15%
Digestive System Inflammation
15%
Pharmacokinetics
15%
Etiology
15%
Pathogenesis
15%
Kinase Signaling
15%
Signal Transduction
15%
Cytokine Signaling
15%
Inflammatory Bowel Disease
15%
Genetics
15%
Diseases
15%
Recurrent Disease
11%
Infection
11%
Antimicrobial Agent
11%
Bacterium
11%
Prevalence
11%
Beta-Lactamase
11%
Hepatic Clearance
11%
Antibiotic Resistant Bacteria
11%
Pyelonephritis
11%
Siderophore
11%
Antiinfective Agent
11%
Cephalosporin
11%
Fall in the Elderly
9%
Dyskinesia
9%
Bradycardia
9%
Retrospective Cohort Study
9%
Hypotension
9%
End Stage Renal Disease
9%
Low Drug Dose
9%
Disorientation
9%
Independent Reviewer
9%
